Brighter has published the results of Actiste® user-experience research conducted at two healthcare centers in
Key findings from the study include:
- 94% of patients rated the capability of ADMS to remind them to take insulin, identify missed insulin doses and increase their understanding of diabetes as "Excellent", "Very good" or "Good".
- 88% of patients also rated as "Excellent", "Very good" or "Good" the capability of ADMS to engage them in their diabetes management.
- 82% of patients said they would recommend the service to a relative or friend with insulin-treated type-2 diabetes and rated ADMS as "Excellent", "Very Good" or "Good".
"We are very pleased and encouraged by the results and feedback received from the research. Clinical and user-experience insights of this nature are of strategic importance for Brighter, as we demonstrate how ADMS may contribute to the improvement of diabetes management", says
"We would like to thank the research participants and the healthcare providers for their kind support, especially as it was challenging to organize and execute research during the Covid-19 pandemic", says Zdravkovic.
For further information, please contact:
Investor Relations
IR@brighter.se
Certified Adviser
Brighter's Certified Adviser is
+46 (0)8 - 684 211 00, adviser@eminova.se, https://eminova.se/
About
Brighter is a health-tech company from
https://news.cision.com/brighter-ab--publ-/r/actiste--receives-positive-ratings-in-user-experience-research,c3476333
https://mb.cision.com/Main/13292/3476333/1513012.pdf
(c) 2021 Cision. All rights reserved., source